Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
15 hedge funds and large institutions have $27.5M invested in Sorrento Therapeutics, Inc. in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$12.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.72M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.95M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.13M |
| 5 |
LMF
LMR Master Fund
Grand Cayman,
Cayman Islands
|
+$994K |
Top Sellers
SRNE Hedge Fund Activity: Q4 2013 in Review
15 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q4 2013, worth a combined $27.5M.
Buyers outnumbered sellers: 15 funds opened new SRNE positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $12.9M.
- 15 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q4 2013, up from 0 in Q3 2013.
- Funds reported $27.5M of Sorrento Therapeutics, Inc. stock for Q4 2013.
- 15 funds opened new Sorrento Therapeutics, Inc. positions in Q4 2013 and 0 closed out, a net change of +15 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q4 2013 was JP Morgan Chase, an estimated $12.9M added.
Based on aggregated 13F filings for Q4 2013.